OncoMatch/Clinical Trials/NCT07006727

Phase I Study of [225Ac]Ac-ETN029 in Patients With Advanced DLL3-expressing Solid Tumors

Is NCT07006727 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies multiple treatments including 225Ac-ETN029 and 111In-ETN029 for small cell lung carcinoma.

Phase 1RecruitingNovartis PharmaceuticalsNCT07006727Data as of May 2026

Treatment: 225Ac-ETN029 · 111In-ETN029 — The purpose of this study is to evaluate the safety, tolerability, dosimetry and preliminary efficacy of \[225Ac\]Ac-ETN029 and the safety and imaging properties of \[111In\]In-ETN029 in patients aged ≥ 18 years with locally advanced or metastatic DLL3 positive cancers.

Check if I qualify

Extracted eligibility criteria

Cancer type

Small Cell Lung Cancer

Neuroendocrine Tumor

Prostate Cancer

Biomarker criteria

Required: DLL3 overexpression

Advanced DLL3-expressing solid tumors

Prior therapy

Min 1 prior line

Must have received: systemic therapy

disease progression following, or intolerance to, at least 1 line of systemic therapy, including platinum-containing chemotherapy, unless patient was ineligible to receive such therapy

Cannot have received: DLL3-targeted therapy

Exception: Prior DLL3-targeted therapy is allowed for SCLC only

Any prior DLL3-targeted therapy (except for SCLC)

Cannot have received: radioligand therapy

Exception: Prior RLT is allowed for NEPC only

any prior RLT (except for NEPC)

Lab requirements

Blood counts

Absolute neutrophil count (ANC) < 1.0 x 10^9/L, hemoglobin < 9 g/dL, or platelet count < 75 x 10^9/L [excluded]

Kidney function

eGFR < 60 mL/min (<0.835 mL/s), calculated using the CKD-EPI 2021 formula or measured [excluded]

Cardiac function

QT interval corrected by Fridericia's formula (QTcF) ≥ 470 msec [excluded]

Absolute neutrophil count (ANC) < 1.0 x 10^9/L, hemoglobin < 9 g/dL, or platelet count < 75 x 10^9/L; QT interval corrected by Fridericia's formula (QTcF) ≥ 470 msec; eGFR < 60 mL/min (<0.835 mL/s), calculated using the CKD-EPI 2021 formula or measured

Structured fields extracted by AI. May contain errors — verify against the official protocol.

US trial sites

University Of Iowa · Iowa City, Iowa
Massachusetts General Hospital · Boston, Massachusetts
Corewell Health William Beaum Hosp · Royal Oak, Michigan

Showing up to 5 US sites. See all sites on ClinicalTrials.gov →

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify